2026 International Congress » Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia

Meeting: 2026 International Congress

A Retrospective Cohort-Based Construction of a Risk Prediction Model for Anxiety or Depression in Parkinson’s Disease and Analysis of Acupuncture Exposure Effects

W. Yixuan, L. Xin, X. Liangman, L. Shumin, Z. Fan, Z. Lixing (Guangzhou, China)

Acute administration of methylphenidate modulates functional connectivity during the processing of irrelevant stimuli in Parkinson’s disease patients

N. Fogelson, L. Li, B. Tan, E. Martinez Lopez, M. Roson Gonzalez, M. Fernandez Delolmo, T. Gurevich, L. Vela Desojo (Fuenlabrada, Spain)

Adult hippocampal neurogenesis and cognitive and neuropsychiatric symptoms in Parkinson’s disease: the MemHiN study

L. Batzu, A. Podlewska, S. Farmand, F. Derbyshire-Fox, A. Woods, N. Crane, C. Pariante, S. Thuret (London, United Kingdom)

Association of Coffee Consumption and Smoking with Cognitive Function in Patients with Early Parkinson’s Disease

SM. Choi, HL. Lee (Gwangju, Republic of Korea)

Can digital Mobility Outcomes differentiate cognitive impairment in Parkinson’s Disease?

P. Ginis, D. Muzyka, V. Shah, L. Alcock, C. Schlenstedt, C. Becker, J. Buekers, B. Caulfield, C. Hansen, S. Del Din, L. Delgado-Ortiz, J. Garcia-Aymerich, H. Gassner, A. Nieuwboer, J. Hausdorff, A. Mirelman, L. Rochester, W. Maetzler, A. Yarnall (Philadelphia, USA)

Cardiovascular Autonomic Dysfunction and Cognitive Impairment in Parkinson’s Disease: A Systematic Review

M. Kakde, S. Kakde, S. Kakade (Pune, India)

Categorization and Characterization of Cognitive Phenotypes in Parkinson’s Disease Using Machine Learning.

H. Trujillo-Guerra, R. Trejo-Ayala, P. Téllez-Hernández, J. Esquivel-Del Río, B. Chávez-Luévanos, I. Estrada-Bellmann, X. Ortiz-Jiménez (Monterrey, Mexico)

Cerebral Small Vessel Disease-Related Degeneration of Cholinergic Pathways Contributes to Cognitive Impairment in Parkinson’s Disease

SM. Rong, XL. Cui, R. Yang, ZH. Li, YH. Zhang, MF. Cai (Guangzhou, Guangdong Province, China)

Changing the ‘Game’: The Impact of ‘Serious Games’-based Cognitive Training on Cognitive Function in Parkinson’s Disease

M. Homes-Vickers, A. Mcnamara, A. Leonard, D. Hobbs, L. Collins-Praino (Adelaide, Australia)

Cholinergic Basal Forebrain Atrophy Associates with Short-Latency Afferent Inhibition and Cognitive Impairment in Parkinson’s Disease

JF. Martín-Rodríguez, P. Franco-Rosado, C. Perez-Calvo, E. Iglesias-Camacho, M. San-Eufrasio, A. Castellano-Guerrero, FJ. Gómez-Campos, P. Díaz-Galván, MA. Labrador-Espinosa, J. Silva-Rodríguez, AC. Luque Ambrosiani, E. Ojeda-Lepe, L. Muñoz-Delgado, D. Macías-García, A. Adarmes-Gómez, S. Jesus, F. Carrillo, F. Roldan Lora, MJ. Grothe, P. Mir (Sevilla, Spain)

Clinical study on acupuncture improving anxiety in Parkinson’s disease by regulating the HPA axis

JQ. Fan, WJ. Lu, X. Liu, YT. Wang, LX. Zhuang (Guangzhou, China)

Cognition and Dementia in a Kenyan Parkinson’s Disease Cohort: A Sub-study of the TraPCAf Consortium

J. Nambafu, D. Sokhi, J. Hooker, M. Pambo, M. Parsemei, B. Mghendi (Nairobi, Kenya)

Cognitive Impairment and Neuropsychiatric Manifestations in Parkinson’s disease in Africa: A Systematic Review of Evidence

M. Njohjam, F. Niakam, M. Ngoule (Dakar, Senegal)

Cognitive Trajectories After STN DBS in Parkinson’s Disease: 12-Month Outcomes

N. Austin, C. O'Keeffe, E. Reynolds, M. Garvey, F. Ruggieri, M. Kelly, C. Moran, R. Walsh (Dublin, Ireland)

Comprehensive Cognitive Assessment Scales and APOE Gene Impact on Cognitive Function in Parkinson’s Disease: A Beijing Population Study

Z. Wu, X. Xue, A. Huang, E. Xu (Beijing, China)

Data-driven Trajectories of Atrophy Explain Clinical Heterogeneity Across Lewy Body Diseases

A. Konuri, G. Leal, T. Transcend Consortium, G. Halliday, S. Lewis, R. Weil, R. Landin-Romero, C. Lambert, N. Oxtoby, E. Matar (Sydney, Australia)

Depression and Psychosis in military Veterans with Parkinson’s Disease (PD)

A. Sarwar, P. Bigner (Houston, USA)

Development and preliminary results of a new self-assessment tool for neuropsychiatric syndromes in Parkinson’s Disease

U. Lambotte, C. Schedlich-Teufer, S. Simon, A. Sauerbier, JC. Baldermann-Weiß, L. Hesse, D. Gruber, G. Ebersbach, W. Jost, E. Kalbe, GR. Fink, J. Kessler, MT. Barbe, SJ. Jost (Wolfach, Germany)

Differentiation of Parkinsonian Syndromes Using Cognitive Strategies and Associations with Non-tremor Motor Progression

A. D'Souza, M. Gibbs, H. Emmett, E. Lwin, C. Sotirakis, C. Antoniades (Oxford, United Kingdom)

Diffusion MRI Markers of Neural Reserve: Interaction Between Callosal Integrity and Clinical Vulnerability After Functional Neurosurgery in Parkinson’s Disease

J. Brainer Lima, M. Cavalcanti, P. Brainer Lima, A. Brainer Lima, M. Sales, S. Laurentino, M. Carvalho, P. Brainer Lima (Recife, Brazil)

Digital cognitive training and promoting a healthy lifestyle as a booster for cognitive reserve in prodromal Parkinson’s disease?

A. Ophey, S. Röttgen, K. Kufer, J. Pauquet, D. Scharfenberg, P. Armbrust, A. Kammerzell, N. Knopf, S. Kollath, P. Sommer, CEJ. Doppler, E. Farrher, A. Seger, NJ. Shah, D. Zopfs, K. Reetz, GR. Fink, M. Sommerauer, E. Kalbe (Cologne, Germany)

Distinct Cognitive Profiles in Parkinson’s and Alzheimer’s Disease: Evidence from a Large Neurodegenerative Cohort

I. Zhukova, M. Matveeva, N. Zhukova, A. Agasheva, D. Novotnyi, S. Shteimetz, Z. Sayfitdinkhuzhaev (Moscow, Russian Federation)

Distinct Neurostructural, Cognitive, and Neuropsychiatric Associations of Plasma p-tau217, and Aβ42/40 in Parkinson’s Disease and Aging Cohorts

E. Fiorenzato, S. Cauzzo, G. Musso, R. Biundo, C. Ceolin, C. Fogliano, C. Cosma, W. Meissner, V. Misenti, S. Moz, ML. Nasi, F. Vianello, R. Manara, M. Montagnana, G. Sergi, A. Antonini (Padova, Italy)

Dopamine depletion does not mitigate striatal reward prediction error signals

JH. Shin, JS. Kim, HK. Chung, MW. Jung (Seoul, Republic of Korea)

Dopaminergic Modulation Of Contextual Emotional Appraisal And Shame In Parkinson’s Disease

S. Catalano Chiuve, D. Benis, C. Rime, M. Maradan-Gachet, J. Potheegadoo, F. Bernasconi, O. Blanke, P. Krack, V. Fleury (Geneva, Switzerland)

Early Caudate Dopaminergic Loss as an Imaging Biomarker of Cognitive Impairment in Parkinson’s Disease: A Longitudinal Analysis

B. Panigrahi, D. Radhakrishnan, R. Rajan (Deoghar, India)

Efficacy of Aripiprazole on Cognitive Functions in Parkinson’s Disease: A Systematic Review and Meta-analysis

I. Serag (Mansoura, Egypt)

Efficacy of Novel Antipsychotic Agents on Cognitive Functions in Parkinson’s Disease: A Systematic Review and Meta-analysis of 2,533 Patients

I. Serag (Mansoura, Egypt)

Electrophysiological Evaluation of Visual Hallucination in Parkinson’s Disease Psychosis

Z. Piazza, G. Schwartz (Stony Brook, USA)

Emergence of Cortical Amyloid from the Prodromal Stage of the Lewy Body Disease Spectrum: Evidence from a PiB-PET Study

M. Yoshita, S. Tsuji, K. Yokoyama (Nanto, Japan)

Episodic Memory Impairment in South Asian Individuals with Parkinson’s Disease: A Pilot Comparative Study

A. Oberoi, B. Riad, E. Stenroos, G. Pal (Shreveport, USA)

Escitalopram for Depression and Motor Symptoms in Parkinson’s Disease: A Systematic Review and Meta‑analysis

V. Byroju, J. Pitton Rissardo, J. Patino, A. Fornari Caprara, A. Mcgarry, I. Walker (Camden, USA)

Evaluating the Relationship between Depression and Other Non-Motor Symptoms in Parkinson’s Disease

TCM. Leung, S. Appel-Cresswell (Vancouver, Canada)

Executive Dysfunction as a Determinant of Functional Impairment in Parkinson’s Disease

N. Adhitama, R. Ibonita, R. Puspa, M. Wedariani, A. Devicaesaria, S. Lumempouw (East Jakarta, Indonesia)

Functional Dyskinesia in a Patient with Parkinson’s Disease: A Diagnostic and Therapeutic Challenge

V. Kotenev, V. Tkachenko, A. Nikitina (Moscow, Russian Federation)

Impact of Amyloid-beta co-pathology on future hallucination in Parkinson’s disease

M. Park (Gwangmyeong, Republic of Korea)

Impact of Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion on Neuropsychiatric Symptoms in Clinical Practice: A Multicenter Study

D. Campo-Caballero, J. Rodríguez-Antigüedad, A. Puig-Davi, J. Ruiz-Martinez, A. Vinagre-Aragón, E. Mondragón, L. Pardina, G. González-Ortega, D. Santos-García (San Sebastian, Spain)

Improving Equitable Access to Parkinson’s Disease Exercise Programs Through a Student-Led Transportation Model

S. Bhagwagar, J. Dempsey, J. Meyer, T. Chabrashvili (Syracuse, USA)

Impulse-compulsive disorders and non-motor symptom profiles in Parkinson’s disease: findings from a Tunisian cohort

E. Cherif, A. Rekik, A. Mili, K. Jemai, A. Hsini, H. Slimen, S. Naija, A. Hassine, S. Ben Amor (Sousse, Tunisia)

Increased Pre-Alpha EEG Functional Connectivity Forecasts Future Cognitive Decline in Parkinson’s Disease

A. Tetereva, G. Hall-Mcmaster, N. Slater, A. Harris, R. Shoorangiz, C. Le Heron, R. Keenan, I. Kirk, W. Meissner, T. Anderson, T. Melzer, N. Pat, J. Dalrymple-Alford (Christchurch, New Zealand)

Investigation of Sex-based Differences in the Utility of IgG Index as a Potential Predictor of Cognitive Impairment in Parkinson’s Disease

R. Edillor, J. Ruiz-Tejeda, R. Rajmohan, N. Phielipp (Irvine, USA)

Latent Classes of Cognitive Decline in Parkinson’s Disease: Neuroimaging and Neurodegenerative Blood Biomarker Correlates

MC. Mckenna, M. Pasternak, R. Alesker, S. Mirza, S. Black, C. Marras, M. Binns, D. Breen, K. Fishman, D. Grimes, B. Levine, P. Mclaughlin, A. Troyer, R. Bartha, H. Zetterberg, A. Lang, M. Masellis (Toronto, Canada)

Longitudinal cognitive variability in isolated and probable REM sleep behaviour disorder using the Trail Making Test

H. Chohan, S. Water, L. Pérez-Carbonell, G. Leschziner, T. Periñán, B. Huxford, S. Eriksson, J. Bestwick, A. Schrag, A. Noyce, C. Simonet (London, United Kingdom)

Multivariate Cognitive Markers of Dementia Progression in Parkinson’s Disease

SY. Kang, SH. Lee, M. Song, MS. Kim, YE. Kim, HI. Ma, Y. Kang (Hwaseong, Republic of Korea)

Neuropsychiatric Symptom Changes in Parkinson’s Disease Patients Treated with Different Doses of Donepezil: A 24-Week Follow-up Study

EJ. Chung (Busan, Republic of Korea)

Neuropsychiatric Symptoms in Lewy Body Disease: Monoaminergic Activity and Resting State Networks

L. Wright, D. Burn, J. Taylor, J. O'Brien, A. Yarnall, M. Firbank, A. Thomas, R. Lawson (Cambridge, United Kingdom)

Nigrostriatal Dopaminergic Patterns in Dementia with Lewy Bodies and Parkinson’s Disease Subtypes: A DAT-SPECT Study within the SOC Framework

G. Palermo, E. Bergamin, G. Bellini, G. Aghakhanyan, D. Frosini, V. Nicoletti, G. Tognoni, D. Volterrani, R. Ceravolo (Pisa, Italy)

Optimal and invariant hierarchical cognitive indices in the Parkinson’s Progression Markers Initiative

D. González, W. Kent, G. Springer, A. Karstens (Chicago, USA)

Parkinson disease psychosis: A systematic review and meta-analysis

J. Hinkle, J. Blackband, B. Garner, K. Perepezko, C. Morrow, A. Chowdhury, K. Mills, A. Mahajan, A. Martinez-Nunez, G. Pontone (Baltimore, USA)

Personality Dynamics and Cognitive Impairment and Related Neuropsychiatric Symptoms in Patience with Different Movement Disorders

M. Kulsum, M. Naaz, A. Das, A. Das, T. Dolai, S. Majumdar (Kolkata, India)

Plasma p-tau217 outperforms p-tau181 as a biomarker of Alzheimer’s disease co-pathology in the Lewy Body Disorders spectrum

Preservation of Cognition Following Intravenous Mesenchymal Stem Cell Therapy in Parkinson’s Disease: Secondary Analysis of a Randomized Trial

J. Martinez-Lemus, T. Thomas, C. Green, T. Ellmore, F. Triolo, S. Olson, J. Suescun, E. Tharp, C. Onuigbo, R. Ritter Iii, M. Schiess (Brisbane City, Australia)

Prevalence and Clinical Determinants of Cognitive Impairment in a Diverse Parkinson’s Disease Cohort

A. Zirra, K. Dey, E. Camboe, E. Bhadra, R. Laban, B. Huxford, S. Hussain-Ali, C. Simonet, C. Budu, D. Gallagher, S. Waters, V. Azoidou, T. Boyle, A. Lees, M. Perinan, C. Marshall, A. Noyce (London, United Kingdom)

Prevalence and clinical predictors of depressive symptoms in Parkinson’s Disease: an analysis from the Global Parkinson’s Genetics Program

P. Reyes-Pérez, T. Perinan, D. Delgado, A. Lazaro-Figueroa, A. Medina-Rivera, A. Ruiz-Contreras, S. Alcauter-Solorzano (Mexico City, Mexico)

Prevalence and Treatment Patterns of Anxiety Symptoms in Parkinson’s Disease

J. Lam, K. Tosefsky, S. Appel-Cresswell (Vancouver, Canada)

Proposed cognitive indices for the Parkinson’s Progression Markers Initiative

D. González, W. Kent, G. Springer, A. Karstens (Chicago, USA)

Psychiatric Profiles in Parkinson: A Cluster Analysis of Cognitive Performance

R. Trejo-Ayala, H. Trujillo-Guerra, P. Téllez-Hernández, K. Trejo-Ayala, B. Chávez-Luévanos, I. Estrada-Bellmann, X. Ortiz-Jiménez (Monterrey, Mexico)

Severity of Psychotic Symptoms Is Independently Associated with Caregiver Burden in Parkinson’s Disease: A Cross-Sectional Analysis

J. Espinoza-Solares, J. López-Moreno, A. Tapia, L. Cortés, JC. Delgado-Uriarte, A. Cervantes-Arriaga, M. Rodriguez-Violante (Mexico City, Mexico)

Sex Differences for Primary Psychiatric Diagnoses and Associated Care Outcomes in Dementia with Lewy Bodies using Epic Cosmos

S. Holden, E. Bayram, S. Aslam, T. Carlisle, M. Fullard, B. Bettcher, V. Pelak (Aurora, USA)

Sex-Specific Associations of APOE ε4 with Cognitive Decline in Parkinson’s Disease: Insights from the Critical Path Institute GEM-PD Initiative

R. Botta, J. Locascio, R. Ye, A. Goodheart, D. Stephenson, S. Gomperts (Tucson, USA)

Social Cognition in Patients with Parkinson’s Disease

A. Kim, M. Kim (Cheongju, Republic of Korea)

Social Network Structure and Caregiving Experiences in South Asian Families Living with Dementia Associated with Parkinsonian Disorders

A. Oberoi, S. Gaur, C. Yang, G. Pal (New Brunswick, USA)

Stakeholder Engagement to Inform Research on Suicidality and Assisted Dying in Parkinson’s

L. Wright, S. Hussain-Ali, A. Noyce, L. Smith (London, United Kingdom)

Strategies for Harmonising Clinical Data for Multi-Centre, Large Scale Genome-Wide Association Studies

M. Martín-Bórnez, E. Navarro-Jones, MT. Periñan, L. Jones, H. Iwaki, H. Morris, R. Real (Sevilla, Spain)

Synergistic Impact of Plasma Neurofilament Light Chain and Neuroimaging Deficits on Cognitive Decline in Prodromal Lewy Body Disease

K. Hiraga, D. Tamakoshi, T. Fukushima, Y. Saito, K. Fuse, T. Uematsu, T. Tsuboi, M. Sato, K. Yokoi, K. Suzuki, Y. Arahata, Y. Washimi, M. Yamamoto, H. Shimizu, M. Wakai, H. Tatebe, T. Tokuda, A. Nakamura, S. Niida, M. Katsuno (Nagoya, Japan)

Temporal Ordering of Biomarker Abnormality Events Leading to Cognitive Impairment in Parkinson’s Disease: A Disease Event-Based Model Analysis of the PPMI Cohort

A. Negida (Richmond, USA)

The Association Between Gastrointestinal Dysfunction and Psychological Health in Individuals with Parkinson’s Disease

M. Messing, N. Meier (Irvine, USA)

The Burden of Cognitive Impairment in People with Parkinson’s across Outpatients and Prevalent Patients in Coastal Kenya: A Transforming Parkinson’s Care in Africa (TraPCAf) Study

R. Morton, S. Mwamba, D. Nyabuto, J. Nambafu, S. Kariuki, D. Sokhi, S. Ahmed, Y. Okkaoglu, C. Dotchin, C. Newton, N. Fothergill-Misbah, N. Okubadejo, R. Walker (Newcastle Upon Tyne, United Kingdom)